Track Pharvaris B.V. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Pharvaris B.V. PHVS · Stock Open Pharvaris B.V. in new tab

33.36 USD
EPS
-3.06
P/B
7.10
ROE
-70.46
Beta
-2.52
Target Price
57.03 USD
Loading chart...
Key Metrics
Earnings dateApril 1, 2027
EPS-3.06
Book Value4.81
Price to Book7.10
Debt/Equity0.22
% Insiders6.306%
Estimates
Forward P/E-11.18
Forward EPS-3.06
Target Mean Price57.03

DCF valuation

Model fair value for Pharvaris B.V. (PHVS)
Result
Sign in to run the valuation for PHVS.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
14 analysts · consensus None · mean target 57.03 USD (low 40.56, high 78.15) · as of 12 Nov 2026
Low 40.56
Mean 57.03
High 78.15
Price 33.36
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

Pharvaris B.V. Logo Pharvaris B.V. Analysis (PHVS)

Netherlands Health Care Official Website Stock

Is Pharvaris B.V. a good investment? Pharvaris B.V. (PHVS) is currently trading at 33.36 USD. Market analysts have a consensus price target of 57.03 USD. This suggests a potential upside from current levels.

Earnings Schedule: Pharvaris B.V. is expected to release its next earnings report on April 1, 2027. The market consensus estimate for Forward EPS is -3.06.

Investor FAQ

Does Pharvaris B.V. pay a dividend?

No, it does not currently pay a dividend.

What asset class is Pharvaris B.V.?

Pharvaris B.V. is classified as a Stock. You can compare it against 3 other assets in the "Related Symbols" list on this page.

When is the next earnings date?

The next earnings date is projected to be April 1, 2027. The company currently has a trailing EPS of -3.06.

Company Profile

Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant. Pharvaris N.V. was incorporated in 2015 and is headquartered in Zug, Switzerland.

Exchange Ticker
NMS (United States) PHVS
DUS (Germany) 9EN.DU
FRA (Germany) 9EN.F
Trades
No dividend information available for this instrument.
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion